AbbVie Inc. — ABBV
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|
| $207.94 | $367.80B | 87.4 | 12.9 | 28.5% | 6.9% | $6.92
3.3% | -112.4 |
Revenue & Net Income
|
Date |
Revenue |
Net_Income |
EPS |
Last_Updated |
Revenue_Change |
Net_Income_Change |
EPS_Change |
| 0 |
2021-12-31 |
$56,197M |
$11,542M |
$6.69 |
2026-02-27 13:24:53 |
N/A |
N/A |
N/A |
| 1 |
2022-12-31 |
$58,054M |
$11,836M |
$6.69 |
2026-04-10 21:48:05 |
3.3% |
2.5% |
0.0% |
| 2 |
2023-12-31 |
$54,318M |
$4,863M |
$2.75 |
2026-04-10 21:48:05 |
-6.4% |
-58.9% |
-58.8% |
| 3 |
2024-12-31 |
$56,334M |
$4,278M |
$2.42 |
2026-04-10 21:48:05 |
3.7% |
-12.0% |
-12.0% |
| 4 |
2025-12-31 |
$61,160M |
$4,226M |
$2.37 |
2026-04-10 21:48:05 |
8.6% |
-1.2% |
-2.2% |
| 5 |
TTM 2025-12-31 |
$61,160M |
$4,226M |
$2.38 |
2026-02-09 08:38:52 |
0.0% |
0.0% |
0.4% |
EPS
Forecasts
Y/Y % Change
YoY Growth Rates
ABBV Year-over-Year Growth
| |
2021 |
2022 |
2023 |
2024 |
2025 |
2026 |
2027 |
Average |
| Revenue Growth (%) |
|
3.3% |
-6.4% |
3.7% |
8.6% |
9.5% |
8.5% |
4.5% |
| Revenue Analysts (#) |
0 |
0 |
0 |
0 |
0 |
8 |
8 |
|
| EPS Growth (%) |
|
2.5% |
-58.9% |
-12.0% |
-1.2% |
505.6% |
11.5% |
74.6% |
| EPS Analysts (#) |
0 |
0 |
0 |
0 |
0 |
10 |
10 |
|
Expenses
| Year |
Revenue ($) |
Cost of Revenue ($) |
R&D ($) |
SG&A ($) |
Facilities / D&A ($) |
| 2021 |
$56.2B |
$8.9B |
$8.0B |
$12.3B |
$8.5B |
| 2022 |
$58.1B |
$8.9B |
$6.5B |
$15.3B |
$8.5B |
| 2023 |
$54.3B |
$11.7B |
$7.7B |
$12.9B |
$8.7B |
| 2024 |
$56.3B |
$8.5B |
$12.8B |
$14.8B |
$8.4B |
| 2025 |
$61.2B |
$10.1B |
$9.1B |
$14.0B |
$8.1B |
| TTM |
$61.2B |
$10.1B |
$9.1B |
$14.0B |
$8.1B |
| Year |
Revenue Change (%) |
Cost of Revenue Change (%) |
R&D Change (%) |
SG&A Change (%) |
Facilities / D&A Change (%) |
| 2022 |
3.30 |
0.25 |
-19.09 |
23.57 |
-0.63 |
| 2023 |
-6.44 |
30.96 |
17.90 |
-15.65 |
2.73 |
| 2024 |
3.71 |
-27.30 |
66.66 |
14.61 |
-3.59 |
| 2025 |
8.57 |
18.16 |
-28.89 |
-5.03 |
-2.95 |
| TTM |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
No unmapped expenses.
Balance Sheet
| |
Metric |
Value |
| 0 |
Total Assets |
$133,898M |
| 1 |
Cash |
$5,629M |
| 2 |
Total Liabilities |
$136,497M |
| 3 |
Total Debt |
$68,743M |
| 4 |
Total Equity |
$-2,642M |
| 5 |
Debt to Equity Ratio |
-26.02 |
EPS & Dividend
Valuation
| Share Price |
Treasury Yield |
Estimates |
Fair Value (P/E) |
Fair Value (P/S) |
Current P/S |
Current P/E |
| $207.94 |
4.3% |
FINVIZ Growth: 21% |
Nicks: 6
Finviz: 49 |
Nick's: 0.000 |
6.0 |
87.4 |
| Basis |
Year |
Nicks Valuation |
Nicks vs Share Price |
Finviz Valuation |
Finviz vs Share Price |
| $2.38 EPS |
TTM |
$15.31 |
-92.6% |
$115.61 |
-44.4% |
| $14.47 EPS |
2026 |
$93.07 |
-55.2% |
$702.89 |
238.0% |
| $16.14 EPS |
2027 |
$103.81 |
-50.1% |
$784.02 |
277.0% |
Implied Growth
|
Average |
Median |
Std Dev |
Current |
Percentile |
|
TTM |
Forward |
TTM |
Forward |
TTM |
Forward |
TTM |
Forward |
TTM |
Forward |
| Timeframe |
|
|
|
|
|
|
|
|
|
|
| 1 Year |
31.53% |
9.20% |
30.14% |
9.15% |
3.49% |
1.21% |
28.76% |
7.12% |
19.5% |
6.3% |
| 3 Years |
31.53% |
9.20% |
30.14% |
9.15% |
3.49% |
1.21% |
28.76% |
7.12% |
19.5% |
6.3% |
| 5 Years |
31.53% |
9.20% |
30.14% |
9.15% |
3.49% |
1.21% |
28.76% |
7.12% |
19.5% |
6.3% |
| 10 Years |
31.53% |
9.20% |
30.14% |
9.15% |
3.49% |
1.21% |
28.76% |
7.12% |
19.5% |
6.3% |
← Back